Navigation Links
Hard-to-Treat Leukemia Cell Subtype Identified
Date:1/14/2009

Discovery suggests new treatments for aggressive form of childhood disease, study says

WEDNESDAY, Jan. 14 (HealthDay News) -- Researchers say they may have identified a subtype of T-lymphoblastic leukemia (T-ALL) in children that does not respond to standard intensive chemotherapy.

Approximately 20 percent of children with T-ALL fair poorly on the same chemotherapy treatments that cure others with the disease, and doctors had been unable to explain why and which patients were least likely to improve.

Reporting online Jan. 14 and in the February edition of The Lancet Oncology, a team at St. Jude Children's Research Hospital in Memphis, Tenn., found that those who didn't respond to treatment had early T-cell precursors (ETPs). Believed to be recent migrants from the bone marrow to the thymus, they are substantially different to the lymphoid cells that standard chemotherapy normally attacks and may be resistant to it, the researchers said.

In a U.S.-based group of study participants, nearly three-quarters of those with ETP-ALL suffered a relapse within a decade, compared with only 10 percent of typical T-ALL patients. In an Italian group of participants, 57 percent of ETP-ALL patients had a relapse within two years, compared with only 14 percent of typical T-ALL patients.

"The high risk of remission failure or subsequent relapse for patients with ETP-ALL, if treated with standard intensive chemotherapy, indicates the need for alternative approaches to treatment," Dr. Dario Campana of St. Jude's department of oncology, said in a news release issued by the journal.

Campana and his team suggested trying alternate treatments for ETP-ALL, such as myeloablative therapy (high-dose chemotherapy) followed by haemopoietic stem-cell transplantation in first remission while other therapies are investigated.

More information

The U.S. National Cancer Institute has more about childhood leukemia.



-- Kevin McKeever



SOURCE: The Lancet Oncology, news release, Jan. 14, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Revolutionary New Technique Uses Onyx to Fill Hard-To-Treat Aneurysms
2. Relaxation training may improve control of hard-to-treat systolic hypertension
3. Blood-clotting protein modified for people with hard-to-treat hemophilia
4. Tackling Hard-to-treat Childhood Cancer by Targeting Epigenetic Changes
5. Tackling a hard-to-treat childhood cancer by targeting epigenetic changes
6. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
7. Study finds heart failure is rare among leukemia patients on imatinib
8. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
9. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
10. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
11. Novel strategy under study for aggressive leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hard-to-Treat Leukemia Cell Subtype Identified
(Date:8/18/2017)... ... August 18, 2017 , ... August ... “Vision & Hearing,” advocating for active, healthy lifestyles and highlighting the importance of ... individuals with hearing impairments and shares the latest innovations in hearing aid technology. ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Dawn Johnson Insurance Group, a ... charity drive to generate community support for efforts to educate the local population on ... for all types of cancer. , Each day in America, roughly 4,600 new ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a ... in east Texas, is launching a regional charity effort to provide publicity assistance ... the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations ...
(Date:8/18/2017)... TX (PRWEB) , ... August 18, 2017 , ... ... management and financial planning firm that serves residential and commercial clients in the ... charity drive to raise community support for the fight against cancer. , Founded ...
(Date:8/18/2017)... ... August 18, 2017 , ... With over 16,000 active ... hormone replacement therapy and integrative medicine, has become a frontrunner for people seeking ... as menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded in 2003 ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Aug. 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Saban as president, effective Aug. 7, 2017. ... decided to pursue other interests and will serve as president ... Paul has served us in multiple leadership roles since he ... Jun. 2015 and has provided decisive, strategic leadership which continues ...
(Date:8/7/2017)... 2017  Endo International plc (NASDAQ: ENDP ... virtually all known U.S. mesh product liability claims and ... known remaining U.S. claims at reasonable values. Under the ... fourth quarter of 2017 and continuing through the fourth ... 2017 results, the Company intends to increase its mesh ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
Breaking Medicine Technology: